Aarhus University Seal / Aarhus Universitets segl

Søren Kragh Moestrup

Macrophage activation markers predict mortality in patients with liver cirrhosis without or with acute-on-chronic liver failure (ACLF).

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Standard

Macrophage activation markers predict mortality in patients with liver cirrhosis without or with acute-on-chronic liver failure (ACLF). / Grønbæk, Henning; Rødgaard-Hansen, Sidsel; Aagaard, Niels Kristian; Arroyo, Vicente; Moestrup, Søren K; Garcia, Elisabet; Solà, Elsa; Domenicali, Marco; Piano, Salvatore; Vilstrup, Hendrik; Møller, Holger Jon; CANONIC study investigators of the EASL-CLIF Consortium.

In: Journal of Hepatology, 04.2016, p. 813-22.

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Harvard

Grønbæk, H, Rødgaard-Hansen, S, Aagaard, NK, Arroyo, V, Moestrup, SK, Garcia, E, Solà, E, Domenicali, M, Piano, S, Vilstrup, H, Møller, HJ & CANONIC study investigators of the EASL-CLIF Consortium. 2016, 'Macrophage activation markers predict mortality in patients with liver cirrhosis without or with acute-on-chronic liver failure (ACLF).', Journal of Hepatology, pp. 813-22. https://doi.org/10.1016/j.jhep.2015.11.021

APA

Grønbæk, H., Rødgaard-Hansen, S., Aagaard, N. K., Arroyo, V., Moestrup, S. K., Garcia, E., Solà, E., Domenicali, M., Piano, S., Vilstrup, H., Møller, H. J., & CANONIC study investigators of the EASL-CLIF Consortium. (2016). Macrophage activation markers predict mortality in patients with liver cirrhosis without or with acute-on-chronic liver failure (ACLF). Journal of Hepatology, 813-22. https://doi.org/10.1016/j.jhep.2015.11.021

CBE

Grønbæk H, Rødgaard-Hansen S, Aagaard NK, Arroyo V, Moestrup SK, Garcia E, Solà E, Domenicali M, Piano S, Vilstrup H, Møller HJ, CANONIC study investigators of the EASL-CLIF Consortium. 2016. Macrophage activation markers predict mortality in patients with liver cirrhosis without or with acute-on-chronic liver failure (ACLF). Journal of Hepatology. 813-22. https://doi.org/10.1016/j.jhep.2015.11.021

MLA

Vancouver

Author

Grønbæk, Henning ; Rødgaard-Hansen, Sidsel ; Aagaard, Niels Kristian ; Arroyo, Vicente ; Moestrup, Søren K ; Garcia, Elisabet ; Solà, Elsa ; Domenicali, Marco ; Piano, Salvatore ; Vilstrup, Hendrik ; Møller, Holger Jon ; CANONIC study investigators of the EASL-CLIF Consortium. / Macrophage activation markers predict mortality in patients with liver cirrhosis without or with acute-on-chronic liver failure (ACLF). In: Journal of Hepatology. 2016 ; pp. 813-22.

Bibtex

@article{40f1ca1b13c14c7eb5626334c949a22b,
title = "Macrophage activation markers predict mortality in patients with liver cirrhosis without or with acute-on-chronic liver failure (ACLF).",
abstract = "BACKGROUND & AIMS: Activation of liver macrophages plays a key role in liver and systemic inflammation and may be involved in development and prognosis of acute-on-chronic liver failure (ACLF). We therefore measured the circulating macrophage activation markers soluble sCD163 and mannose receptor (sMR) and related them to the short-(1-3 months) and long-term (6 months) mortality in the cirrhosis patients of the CANONIC study. METHODS: Eighty-six cirrhosis patients had no ascites and no ACLF, 580 had ascites but no ACLF; 100, 66, and 19 had ACLF-grade-I (ACLF-I), ACLF-II, and ACLF-III, respectively. The patients' clinical course was registered and their MELD, CLIF-C Acute Decompensation (AD), and CLIF-C ACLF-scores computed at inclusion. RESULTS: We found a stepwise increase (p<0.001) in median sCD163 (5.68 (IQR: 3.86-9.60); 8.26 (5.02-12.34); 9.50 (5.37-17.91); 15.68 (10.12-19.42); 20.18 (15.26-32.20) mg/L) and sMR (0.60 (0.40-0.84); 0.81 (0.57-1.12); 0.81 (0.61-1.26); 1.17 (0.89-1.62); 1.41 (1.14-1.79)mg/L) with increasing grades of ACLF. Both sCD163 and sMR were independently associated with short and long-term mortality and showed equal or higher predictive accuracy than MELD, CLIF-C ACLF and CLIF-C AD scores. Addition of the macrophage markers to the clinical scores improved the prognostic efficacy: In ACLF patients sCD163 improved prediction of short-term mortality (C-index: 0.74 (0.67-0.80)) and in patients without ACLF sMR improved prediction of long-term mortality (C-index: 0.80 (0.76-0.85)). CONCLUSIONS: The severity related increase in sCD163 and sMR and close association with mortality suggest a primary importance of inflammatory activation of liver macrophages in the emergence and course of ACLF. Accordingly, supplementation of the macrophage biomarkers to the platform of the clinical scores improved the prognostic performance beyond that of the original scores. ",
keywords = "Acute-on-chronic liver failure, Biomarker, CD163, Cirrhosis, Cirrhosis complications, Macrophages, Mannose receptor, Prognosis, Acute-on-chronic liver failure, Biomarker, CD163, Cirrhosis, Cirrhosis complications, Mocrophages, Mannose receptor, Prognosis",
author = "Henning Gr{\o}nb{\ae}k and Sidsel R{\o}dgaard-Hansen and Aagaard, {Niels Kristian} and Vicente Arroyo and Moestrup, {S{\o}ren K} and Elisabet Garcia and Elsa Sol{\`a} and Marco Domenicali and Salvatore Piano and Hendrik Vilstrup and M{\o}ller, {Holger Jon} and {CANONIC study investigators of the EASL-CLIF Consortium.}",
note = "Copyright {\textcopyright} 2015. Published by Elsevier B.V.",
year = "2016",
month = apr,
doi = "10.1016/j.jhep.2015.11.021",
language = "English",
pages = "813--22",
journal = "Journal of Hepatology",
issn = "0168-8278",
publisher = "Elsevier BV",

}

RIS

TY - JOUR

T1 - Macrophage activation markers predict mortality in patients with liver cirrhosis without or with acute-on-chronic liver failure (ACLF).

AU - Grønbæk, Henning

AU - Rødgaard-Hansen, Sidsel

AU - Aagaard, Niels Kristian

AU - Arroyo, Vicente

AU - Moestrup, Søren K

AU - Garcia, Elisabet

AU - Solà, Elsa

AU - Domenicali, Marco

AU - Piano, Salvatore

AU - Vilstrup, Hendrik

AU - Møller, Holger Jon

AU - CANONIC study investigators of the EASL-CLIF Consortium.

N1 - Copyright © 2015. Published by Elsevier B.V.

PY - 2016/4

Y1 - 2016/4

N2 - BACKGROUND & AIMS: Activation of liver macrophages plays a key role in liver and systemic inflammation and may be involved in development and prognosis of acute-on-chronic liver failure (ACLF). We therefore measured the circulating macrophage activation markers soluble sCD163 and mannose receptor (sMR) and related them to the short-(1-3 months) and long-term (6 months) mortality in the cirrhosis patients of the CANONIC study. METHODS: Eighty-six cirrhosis patients had no ascites and no ACLF, 580 had ascites but no ACLF; 100, 66, and 19 had ACLF-grade-I (ACLF-I), ACLF-II, and ACLF-III, respectively. The patients' clinical course was registered and their MELD, CLIF-C Acute Decompensation (AD), and CLIF-C ACLF-scores computed at inclusion. RESULTS: We found a stepwise increase (p<0.001) in median sCD163 (5.68 (IQR: 3.86-9.60); 8.26 (5.02-12.34); 9.50 (5.37-17.91); 15.68 (10.12-19.42); 20.18 (15.26-32.20) mg/L) and sMR (0.60 (0.40-0.84); 0.81 (0.57-1.12); 0.81 (0.61-1.26); 1.17 (0.89-1.62); 1.41 (1.14-1.79)mg/L) with increasing grades of ACLF. Both sCD163 and sMR were independently associated with short and long-term mortality and showed equal or higher predictive accuracy than MELD, CLIF-C ACLF and CLIF-C AD scores. Addition of the macrophage markers to the clinical scores improved the prognostic efficacy: In ACLF patients sCD163 improved prediction of short-term mortality (C-index: 0.74 (0.67-0.80)) and in patients without ACLF sMR improved prediction of long-term mortality (C-index: 0.80 (0.76-0.85)). CONCLUSIONS: The severity related increase in sCD163 and sMR and close association with mortality suggest a primary importance of inflammatory activation of liver macrophages in the emergence and course of ACLF. Accordingly, supplementation of the macrophage biomarkers to the platform of the clinical scores improved the prognostic performance beyond that of the original scores.

AB - BACKGROUND & AIMS: Activation of liver macrophages plays a key role in liver and systemic inflammation and may be involved in development and prognosis of acute-on-chronic liver failure (ACLF). We therefore measured the circulating macrophage activation markers soluble sCD163 and mannose receptor (sMR) and related them to the short-(1-3 months) and long-term (6 months) mortality in the cirrhosis patients of the CANONIC study. METHODS: Eighty-six cirrhosis patients had no ascites and no ACLF, 580 had ascites but no ACLF; 100, 66, and 19 had ACLF-grade-I (ACLF-I), ACLF-II, and ACLF-III, respectively. The patients' clinical course was registered and their MELD, CLIF-C Acute Decompensation (AD), and CLIF-C ACLF-scores computed at inclusion. RESULTS: We found a stepwise increase (p<0.001) in median sCD163 (5.68 (IQR: 3.86-9.60); 8.26 (5.02-12.34); 9.50 (5.37-17.91); 15.68 (10.12-19.42); 20.18 (15.26-32.20) mg/L) and sMR (0.60 (0.40-0.84); 0.81 (0.57-1.12); 0.81 (0.61-1.26); 1.17 (0.89-1.62); 1.41 (1.14-1.79)mg/L) with increasing grades of ACLF. Both sCD163 and sMR were independently associated with short and long-term mortality and showed equal or higher predictive accuracy than MELD, CLIF-C ACLF and CLIF-C AD scores. Addition of the macrophage markers to the clinical scores improved the prognostic efficacy: In ACLF patients sCD163 improved prediction of short-term mortality (C-index: 0.74 (0.67-0.80)) and in patients without ACLF sMR improved prediction of long-term mortality (C-index: 0.80 (0.76-0.85)). CONCLUSIONS: The severity related increase in sCD163 and sMR and close association with mortality suggest a primary importance of inflammatory activation of liver macrophages in the emergence and course of ACLF. Accordingly, supplementation of the macrophage biomarkers to the platform of the clinical scores improved the prognostic performance beyond that of the original scores.

KW - Acute-on-chronic liver failure

KW - Biomarker

KW - CD163

KW - Cirrhosis

KW - Cirrhosis complications

KW - Macrophages

KW - Mannose receptor

KW - Prognosis

KW - Acute-on-chronic liver failure

KW - Biomarker

KW - CD163

KW - Cirrhosis

KW - Cirrhosis complications

KW - Mocrophages

KW - Mannose receptor

KW - Prognosis

U2 - 10.1016/j.jhep.2015.11.021

DO - 10.1016/j.jhep.2015.11.021

M3 - Journal article

C2 - 26639396

SP - 813

EP - 822

JO - Journal of Hepatology

JF - Journal of Hepatology

SN - 0168-8278

ER -